Last updated: February 27, 2026
What is the drug associated with NDC 62135-0512?
NDC 62135-0512 corresponds to Tepmetko (tepotinib), developed by Merck KGaA. Tepmetko is an oral kinase inhibitor approved in the U.S. for the treatment of c-MET-driven non-small cell lung cancer (NSCLC).
What is the current market size for Tepmetko?
Market penetration
- Approved by the FDA in April 2022.
- Targeted at patients with MET exon 14 skipping alterations.
- Estimated prevalence in NSCLC: 3-4% of all NSCLC cases.
- U.S. NSCLC annual incidence (2022): approximately 236,000 new cases [1].
Addressable patient population
- Estimated U.S. patients with MET exon 14 alterations: 7,000–9,000 annually.
- Market penetration in first 2 years: approximately 10–15%, given awareness and diagnostic adoption.
Estimated revenue potential
Assumed average treatment duration: 12 months.
- Average wholesale price (AWP): $11,000 per month per patient (based on competitive kinase inhibitors).
- Estimated initial annual revenue (year 1):
[
9,000 \text{ patients} \times\$11,000 \times 12 \text{ months} = \$1.188 \text{ billion}
]
- Market share adjustments and clinical adoption rates could reduce this potential; expecting 20–40% penetration within 2 years.
How does the commercialization landscape look?
Competitive landscape
- Only one FDA-approved drug for MET exon 14 skipping NSCLC.
- Key competitors include crizotinib (Xalkori) and capmatinib (Tabrecta).
- Tepmetko’s differentiated efficacy against resistance mutations and safety profile impact market share.
Reimbursement and access
- Medicare and private insurance coverage aligns with recent approvals.
- Pricing negotiations influence final payer acceptance.
Diagnostic test integration
- Companion diagnostic testing increased from 35% in 2021 to 60% in 2022 [2].
- Accelerates market access but requires time for reimbursement policies to stabilize.
Price projections for the upcoming 3-5 years
Year 1:
- Price range: $10,000–$12,000 per month.
- Revenue estimate: $1–1.2 billion (assuming 75% of target population treated).
Year 2:
- Price adjustments expected based on payer negotiations.
- Likely slight discounts or rebates reducing the AWP to $9,500–$11,000 per month.
- Revenue growth: 10–15%, driven by increased diagnostic adoption and market penetration.
Year 3–5:
- Price stabilization around $9,500–$10,500 per month.
- Annual revenue projections:
- Year 3: approximately $1.2 billion.
- Year 4: up to $1.4 billion.
- Year 5: growth slows as maximum market penetration approaches.
Influencing factors:
- Competition introductions.
- Diagnostic test accessibility.
- Payer reimbursement rates.
- Off-label use and expanded indications.
Key considerations
- Pricing strategies will be driven by negotiations, peg to existing targeted therapies.
- Market acceptance depends on real-world efficacy data.
- Patent protections extend until at least 2030, supporting long-term pricing power.
Key Takeaways
- Tepmetko holds a targeted, niche market within advanced NSCLC.
- Market size in the U.S. could reach approximately $1–1.2 billion in annual revenue at peak penetration.
- Price points are expected to hover around $10,000–$12,000 per month for the initial years, adjusting downward as competition and payer negotiations influence the landscape.
- Growth depends on diagnostic adoption, clinical trial outcomes, and competitive entries.
FAQs
Q1: What factors could alter Tepmetko’s market penetration?
A: Changes in diagnostic testing rates, clinical guideline updates, and competitor drug approvals.
Q2: How does Tepmetko’s price compare to similar kinase inhibitors?
A: It is within the range of $9,000–$15,000 per month for comparable targeted therapies.
Q3: When could generic or biosimilar versions impact pricing?
A: Likely after patent expiry, possibly post-2030, pending patent litigation and biosimilar development.
Q4: How might insurance coverage influence pricing projections?
A: Improved reimbursement could sustain higher prices; payer pushback may lead to discounts.
Q5: What are the main risks to revenue growth?
A: Rapid competition, limited diagnostic adoption, and unforeseen clinical trial setbacks.
References
[1] American Cancer Society. (2022). Cancer Facts & Figures 2022.
[2] IQVIA. (2022). Diagnostic Test Market Share Report.
